Initial capital base of US$200 million, acting as a catalyst to unlock further capital and attract high-quality, scalable investment opportunities aligned with Oman Vision...
Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube Ventures, Surveyor...
Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube Ventures, Surveyor...
The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...
The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...
In this 2025 release, Ageless Shoulders expands its digital shoulder mobility system using traditional Indian club exercises to support joint flexibility, address frozen shoulder limitations, and meet rising search demand for non-surgical, at-home movement programs.
In this 2025 release, Ageless Shoulders expands its digital shoulder mobility system using traditional Indian club exercises to support joint flexibility, address frozen shoulder limitations, and meet rising search demand for non-surgical, at-home movement programs.
BANGKOK, July 8, 2025 /PRNewswire/ -- SKYWORTH PV, the renewable energy arm of China's electronics giant SKYWORTH Group, unleashed a dual-force clean energy offensive...
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reckitt Benckiser Group plc (OTC:RBGLY), UroGen Pharma Ltd. (NASDAQ:URGN), Red Cat Holdings, Inc. (NASDAQ: RCAT) and Fortrea Holdings Inc. (NASDAQ:FTRE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./
TORONTO, July 7, 2025 /CNW/ - Canada Nickel Company...
-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population --
-- Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo --
The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation
MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/...
LOUISVILLE, Ky., July 4, 2025 /PRNewswire/ -- RITFIT, a leading global home fitness brand, has made a groundbreaking announcement at the HomeGymCon 2025, revealing its...
DALLAS, July 4, 2025 /CNW/ - Petro-Victory Energy Corp. (TSXV: VRY) ("Petro-Victory" or the "Company") and Azevedo & Travassos Energia S.A. ("ATE") are pleased to...